Oncopeptides Q1 2025: Strong Q/Q Growth with Japan the Next Catalyst - Redeye

Redey comments on Oncopeptides’ first quarter report 2025. The growth quarter on quarter was 34%, despite a 5% FX headwind. Discussions about a potential deal in Japan are still ongoing. We believe the sales growth trend is stabilising with growing uptake from new markets.

Länk till analysen i sin helhet: https://www.redeye.se/research/1110471/oncopeptides-q1-2025-increasing-visibility-towards-profitability?utm_source=finwire&utm_medium=RSS